New MembersLifeSciences BC welcomes the following new sponsor at the Gold level:LifeScan As a leader in blood glucose monitoring, LifeScan Canada is working to bring about the next important advances in diabetes care. LifeSciences BC welcomes the following new sponsors at the Silver level: Bayer Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Their products and services are designed to benefit people and improve their quality of life. Gowlings Lafleur Henderson LLP For more than 100 years, Gowlings has provided a broad range of expert legal services. Today, as one of Canada's largest national law firms, Gowlings has offices in all major business and technology centres across Canada. LifeSciences BC welcomes the following new sponsors at the Bronze level: Fasken Martineau Fasken Martineau is one of the world's leading international business law and litigation firms with more than 650 lawyers with offices in Canada, the United Kingdom, South Africa and the United States. Their practice includes every sector of business, industry and government. Mayo Clinical Trial Services Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. LifeSciences BC welcomes the following new members: Amorfix Life Sciences Ltd. Arbutus Dental Centre Augurex Life Sciences Corp. Bayer Inc. Bristol-Myers Squibb Canada EaglePicher Corporation Eli Lilly Canada Inc. Farabloc Development Corporation Fulcrum Pharma Globe Laboratories Inc. LifeScan Canada Ltd. Mayo Clinic - Clinical Trial Services McCarthy Consultant Services Inc. MDMI Technologies Inc. Neurodyne Inc. NSERC Pacific Renegade Strategies Inc. Rocket Builders Skye Blue Publications Ltd. SMC Pneumatics (Canada) Ltd. StarFish Medical The State of Illinois UBC MRI Research Centre VanRx Pharmaceuticals Inc. Wisdahl Consulting Group Wyeth Canada Drug assessment, investigational drug development and clinical trials offered at BC Cancer's Investigational Drug Program IDP: From Concept to Clinic The mandate of the Investigational Drug Program (IDP) at the BC Cancer Agency (BCCA) is to expedite the development of promising new therapeutic agents to the initial stage of early clinical trials. As a comprehensive unit, IDP offers a full range of services in three basic areas: i) pre-clinical drug assessment including toxicology, ii) formal investigational drug development and cGMP manufacturing and iii) clinical trials conducted at the BCCA. These three components integrate seamlessly to move novel anti-cancer therapies into first-in-man studies. IDP has expertise with a variety of drug classes, including conventional small molecule drugs and immunotherapy through to the latest gene therapy approaches. Scientists and oncologists working at the BC Cancer Agency have capabilities unmatched in Canada to develop and evaluate new strategies for the treatment of cancer. At present, IDP is the only facility in British Columbia able to develop anti-cancer therapeutics from bench through to early stage clinical evaluations, a continuity of service from formulation to trial that is of immeasurable benefit to the research and biotechnology sectors of the Province as well as to academia. Read more |
 Suite 900 - 1188 West Georgia St.
Vancouver, BC V6E 4A2 |